中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

奥沙利铂对肝星状细胞活化的影响及机制探讨

王存凯 王一军 王丹丹 谢肖立 刘红玉 白云 姜慧卿 王玉珍

引用本文:
Citation:

奥沙利铂对肝星状细胞活化的影响及机制探讨

DOI: 10.12449/JCH240612
基金项目: 

河北省2023年度医学科学研究课题 (20230019)

利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:王存凯负责设计论文框架,起草论文;王存凯、王一军、谢肖立负责实验操作,研究过程的实施;王丹丹、白云负责数据整理、统计学分析;刘红玉负责论文修改;王玉珍、姜慧卿负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    王玉珍, wyzhen211@126.com (ORCID: 0009-0001-4437-4616)

Effect of oxaliplatin on the activation of hepatic stellate cells and its mechanism

Research funding: 

Medical Science Research Project of Hebei Province in 2023 (20230019)

More Information
    Corresponding author: WANG Yuzhen, wyzhen211@126.com (ORCID: 0009-0001-4437-4616)
  • 摘要:   目的  观察奥沙利铂对肝星状细胞(HSC)活化的影响,进一步探讨奥沙利铂与microRNA-30a-5p及自噬的关系。  方法  培养HSC-LX2并做如下分组:(1)对照组、PDGF处理组、奥沙利铂处理组、奥沙利铂+PDGF处理组;(2)对照组、microRNA-30a-5p转染组,PDGF处理组、microRNA-30a-5p转染+PDGF处理组;(3)对照组、3-MA组、microRNA-30a-5p抑制剂组、microRNA-30a-5p抑制剂+3-MA组。应用免疫蛋白印迹技术(Western Blot)分析HSC活化相关蛋白Ⅰ型胶原(Collagen-‍Ⅰ)、抗α-平滑肌肌动蛋白(α-SMA)及HSC自噬相关蛋白Beclin 1、p62、LC3B的表达;溶酶体示踪剂和免疫荧光检测LC3B自噬小体的表达。实时荧光定量PCR(RT-PCR)检测microRNA-30a-5p表达水平。应用生物信息学技术预测microRNA-30a-5p在HSC中的潜在靶点。正态分布的计量资料两组间比较采用成组t检验;多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验。  结果  应用奥沙利铂处理细胞时,RT-PCR结果显示奥沙利铂处理组microRNA-30a-5p的表达水平高于对照组(P<0.01);Western Blot结果显示奥沙利铂处理组的HSC活化相关蛋白α-SMA、Collagen-Ⅰ及自噬相关蛋白Beclin 1、LC3BⅡ/Ⅰ水平均降低(P值均<0.001);免疫荧光结果显示奥沙利铂处理组自噬小体低于对照组(P<0.05)。进一步应用microRNA-30a-5p模拟类似物(mimic)转染HSC-LX2结果显示,与对照组相比,microRNA-30a-5p mimic组自噬相关蛋白Beclin 1和LC3BⅡ/Ⅰ的表达水平均降低(P值均<0.05);HSC活化相关蛋白Collagen-Ⅰ的表达水平亦降低(P<0.001);应用microRNA-30a-5p抑制剂转染HSC-LX2,Western Blot结果显示,与对照组比较,microRNA-30a-5p抑制剂组HSC活化相关蛋白Collagen-Ⅰ、α-SMA,自噬相关蛋白Beclin 1的表达水平均升高(t值分别为2.412.324.57,P值均<0.05)。Western Blot结果显示,与对照组相比,microRNA-30a-5p抑制剂组HSC自噬相关蛋白Beclin 1及活化相关蛋白α-SMA表达水平均升高(P值均<0.05),应用自噬抑制剂3-MA处理后,两组间上述蛋白表达无显著差异(P>0.05)。通过TargetScan、PicTar和miRanda生物信息软件分析表明,自噬相关蛋白Beclin 1是microRNA-30a-5p的潜在靶标。  结论  奥沙利铂可通过上调microRNA-30a-5p表达从而抑制HSC激活,为肝纤维化的治疗提供新的思路和作用靶点。

     

  • 图  1  不同浓度的奥沙利铂对HSC-LX2活性的影响

    Figure  1.  The effect of different concentrations of oxaliplatin on the survival rate of HSC-LX2

    图  2  奥沙利铂抑制HSC自噬和活化相关蛋白的表达

    Figure  2.  Oxaliplatin inhibits the activation and autophagy of HSC

    图  3  LC3B 的Lysotracker red和免疫荧光(×200)

    Figure  3.  LC3B expression observed by Lysotracker red and immunofluorescence(×200)

    图  4  不同浓度的奥沙利铂对microRNA-30a-5p表达量的影响

    Figure  4.  The effect of different concentrations of oxaliplatin on the expression of microRNA-30a-5p

    图  5  HSC-LX2中的microRNA-30a-5p水平

    Figure  5.  The microRNA-30a-5p levels in LX-2

    图  6  PDGF处理后microRNA-30a-5p表达情况

    Figure  6.  microRNA-30a-5p levels in HSC-LX2 with PDGF

    图  7  microRNA-30a-5p抑制HSC-LX2自噬及活化

    Figure  7.  microRNA-30a-5p inhibits autophagy and activation of HSC-LX2

    图  8  microRNA-30a-5p抑制剂促进HSC-LX2自噬及活化

    Figure  8.  microRNA-30a-5p inhibitors promote autophagy and activation of HSC-LX2

    图  9  3-MA阻断microRNA-30a-5p抑制剂促进HSC活化的作用

    Figure  9.  3-MA blocks the effect of microRNA-30a-5p inhibitors in promoting HSC activation

  • [1] WEISKIRCHEN R, TACKE F. Liver fibrosis: From pathogenesis to novel therapies[J]. Dig Dis, 2016, 34( 4): 410- 422. DOI: 10.1159/000444556.
    [2] AYDIN MM, AKCALI KC. Liver fibrosis[J]. Turk J Gastroenterol, 2018, 29( 1): 14- 21. DOI: 10.5152/tjg.2018.17330.
    [3] BANSAL MB, CHAMROONKUL N. Antifibrotics in liver disease: Are we getting closer to clinical use?[J]. Hepatol Int, 2019, 13( 1): 25- 39. DOI: 10.1007/s12072-018-9897-3.
    [4] History GEERTS A., heterogeneity, biology developmental, and functions of quiescent hepatic stellate cells[J]. Semin Liver Dis, 2001, 21( 3): 311- 335. DOI: 10.1055/s-2001-17550.
    [5] ZHANG CY, YUAN WG, HE P, et al. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets[J]. World J Gastroenterol, 2016, 22( 48): 10512- 10522. DOI: 10.3748/wjg.v22.i48.10512.
    [6] YAMAGUCHI K, YANG L, MCCALL S, et al. Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis[J]. Hepatology, 2008, 47( 2): 625- 635. DOI: 10.1002/hep.21988.
    [7] HERNÁNDEZ-GEA V, GHIASSI-NEJAD Z, ROZENFELD R, et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues[J]. Gastroenterology, 2012, 142( 4): 938- 946. DOI: 10.1053/j.gastro.2011.12.044.
    [8] SAITO T, KUMA A, SUGIURA Y, et al. Autophagy regulates lipid metabolism through selective turnover of NCoR1[J]. Nat Commun, 2019, 10( 1): 1567. DOI: 10.1038/s41467-019-08829-3.
    [9] TSUKAMOTO H. Cytokine regulation of hepatic stellate cells in liver fibrosis[J]. Alcohol Clin Exp Res, 1999, 23( 5): 911- 916.
    [10] LI JT, LIAO ZX, PING J, et al. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies[J]. J Gastroenterol, 2008, 43( 6): 419- 428. DOI: 10.1007/s00535-008-2180-y.
    [11] KITANO M, BLOOMSTON PM. Hepatic stellate cells and microRNAs in pathogenesis of liver fibrosis[J]. J Clin Med, 2016, 5( 3): 38. DOI: 10.3390/jcm5030038.
    [12] GRIMSON A, FARH KKH, JOHNSTON WK, et al. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing[J]. Mol Cell, 2007, 27( 1): 91- 105. DOI: 10.1016/j.molcel.2007.06.017.
    [13] IORIO MV, CROCE CM. Causes and consequences of microRNA dysregulation[J]. Cancer J, 2012, 18( 3): 215- 222. DOI: 10.1097/PPO.0b013e318250c001.
    [14] LU RQ, ZHAO G, YANG YL, et al. Long noncoding RNA HOTAIRM1 inhibits cell progression by regulating miR-17-5p/PTEN axis in gastric cancer[J]. J Cell Biochem, 2019, 120( 4): 4952- 4965. DOI: 10.1002/jcb.27770.
    [15] FENG MH, LI JW, SUN HT, et al. Sulforaphane inhibits the activation of hepatic stellate cell by miRNA-423-5p targeting suppressor of fused[J]. Hum Cell, 2019, 32( 4): 403- 410. DOI: 10.1007/s13577-019-00264-2.
    [16] YU XX, RUAN Y, SHEN T, et al. Dexrazoxane protects cardiomyocyte from doxorubicin-induced apoptosis by modulating miR-17-5p[J]. Biomed Res Int, 2020, 2020: 5107193. DOI: 10.1155/2020/5107193.
    [17] HAZARI Y, BRAVO-SAN PEDRO JM, HETZ C, et al. Autophagy in hepatic adaptation to stress[J]. J Hepatol, 2020, 72( 1): 183- 196. DOI: 10.1016/j.jhep.2019.08.026.
    [18] APPS MG, CHOI EHY, WHEATE NJ. The state-of-play and future of platinum drugs[J]. Endocr Relat Cancer, 2015, 22( 4): R219- R233. DOI: 10.1530/ERC-15-0237.
    [19] TAN SF, SHI HJ, BA MC, et al. MiR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy[J]. Int J Mol Med, 2016, 37( 4): 1030- 1038. DOI: 10.3892/ijmm.2016.2492.
    [20] ZHU H, WU H, LIU XP, et al. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells[J]. Autophagy, 2009, 5( 6): 816- 823. DOI: 10.4161/auto.9064.
    [21] TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383( 9930): 1749- 1761. DOI: 10.1016/S0140-6736(14)60121-5.
    [22] POPOV Y, SCHUPPAN D. Targeting liver fibrosis: Strategies for development and validation of antifibrotic therapies[J]. Hepatology, 2009, 50( 4): 1294- 1306. DOI: 10.1002/hep.23123.
    [23] FRIEDMAN SL. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver[J]. Physiol Rev, 2008, 88( 1): 125- 172. DOI: 10.1152/physrev.00013.2007.
    [24] KISSELEVA T, BRENNER DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis[J]. J Gastroenterol Hepatol, 2007, 22( Suppl 1): S73- S78. DOI: 10.1111/j.1440-1746.2006.04658.x.
    [25] WANG J, CHU ESH, CHEN HY, et al. MicroRNA-29b prevents liver fibrosis by attenuating hepatic stellate cell activation and inducing apoptosis through targeting PI3K/AKT pathway[J]. Oncotarget, 2015, 6( 9): 7325- 7338. DOI: 10.18632/oncotarget.2621.
    [26] OKADA H, HONDA M, CAMPBELL JS, et al. Inhibition of microRNA-214 ameliorates hepatic fibrosis and tumor incidence in platelet-derived growth factor C transgenic mice[J]. Cancer Sci, 2015, 106( 9): 1143- 1152. DOI: 10.1111/cas.12730.
    [27] KLINKHAMMER BM, FLOEGE J, BOOR P. PDGF in organ fibrosis[J]. Mol Aspects Med, 2018, 62: 44- 62. DOI: 10.1016/j.mam.2017.11.008.
  • 加载中
图(9)
计量
  • 文章访问数:  200
  • HTML全文浏览量:  87
  • PDF下载量:  28
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-09-06
  • 录用日期:  2023-10-26
  • 出版日期:  2024-06-25
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回